Alps Advisors Inc. increased its position in Enanta Pharmaceuticals Inc (NASDAQ:ENTA) by 6.0% in the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 33,135 shares of the biotechnology company’s stock after purchasing an additional 1,872 shares during the quarter. Alps Advisors Inc. owned approximately 0.17% of Enanta Pharmaceuticals worth $3,840,000 as of its most recent SEC filing.

A number of other hedge funds have also recently made changes to their positions in ENTA. Wells Fargo & Company MN raised its stake in Enanta Pharmaceuticals by 8.2% in the first quarter. Wells Fargo & Company MN now owns 25,306 shares of the biotechnology company’s stock worth $2,048,000 after buying an additional 1,918 shares in the last quarter. New York State Teachers Retirement System raised its stake in Enanta Pharmaceuticals by 3.4% in the first quarter. New York State Teachers Retirement System now owns 39,790 shares of the biotechnology company’s stock worth $3,219,000 after buying an additional 1,300 shares in the last quarter. Boston Family Office LLC bought a new position in Enanta Pharmaceuticals in the first quarter worth approximately $223,000. Algert Global LLC bought a new position in Enanta Pharmaceuticals in the first quarter worth approximately $572,000. Finally, SG Americas Securities LLC bought a new position in Enanta Pharmaceuticals in the first quarter worth approximately $112,000. Hedge funds and other institutional investors own 77.59% of the company’s stock.

NASDAQ ENTA opened at $90.01 on Friday. Enanta Pharmaceuticals Inc has a 12-month low of $41.83 and a 12-month high of $127.77. The firm has a market capitalization of $1.78 billion, a price-to-earnings ratio of 98.84 and a beta of 0.92.

Enanta Pharmaceuticals (NASDAQ:ENTA) last released its quarterly earnings results on Tuesday, August 7th. The biotechnology company reported $0.97 earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of $0.98 by ($0.01). Enanta Pharmaceuticals had a return on equity of 25.84% and a net margin of 37.63%. The firm had revenue of $57.26 million during the quarter, compared to analysts’ expectations of $56.59 million. sell-side analysts anticipate that Enanta Pharmaceuticals Inc will post 3.56 EPS for the current fiscal year.

In other Enanta Pharmaceuticals news, VP Nathalie Adda sold 4,155 shares of Enanta Pharmaceuticals stock in a transaction on Monday, August 20th. The shares were sold at an average price of $92.32, for a total value of $383,589.60. Following the transaction, the vice president now directly owns 4,465 shares of the company’s stock, valued at $412,208.80. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Treasurer Paul J. Mellett sold 15,000 shares of Enanta Pharmaceuticals stock in a transaction on Monday, June 11th. The stock was sold at an average price of $120.57, for a total transaction of $1,808,550.00. Following the completion of the transaction, the treasurer now directly owns 88,158 shares in the company, valued at $10,629,210.06. The disclosure for this sale can be found here. Insiders sold 63,355 shares of company stock worth $7,682,559 over the last ninety days. Corporate insiders own 10.56% of the company’s stock.

ENTA has been the subject of a number of recent research reports. Zacks Investment Research raised shares of Enanta Pharmaceuticals from a “hold” rating to a “strong-buy” rating and set a $111.00 price objective for the company in a research note on Thursday, May 3rd. BidaskClub downgraded shares of Enanta Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research note on Wednesday, May 23rd. Oppenheimer initiated coverage on shares of Enanta Pharmaceuticals in a research note on Thursday, May 24th. They issued a “buy” rating and a $135.00 price objective for the company. Roth Capital initiated coverage on shares of Enanta Pharmaceuticals in a research note on Wednesday, June 6th. They issued a “buy” rating and a $133.00 price objective for the company. Finally, JMP Securities reissued a “buy” rating and issued a $120.00 price objective on shares of Enanta Pharmaceuticals in a research note on Tuesday, July 31st. Six investment analysts have rated the stock with a hold rating, two have issued a buy rating and one has assigned a strong buy rating to the company. Enanta Pharmaceuticals presently has an average rating of “Hold” and an average price target of $107.60.

About Enanta Pharmaceuticals

Enanta Pharmaceuticals, Inc, a biotechnology company, focuses on discovering and developing small molecule drugs for the treatment of viral infections and liver diseases. The company's research and development focuses on disease targets: hepatitis B virus, non-alcoholic steatohepatitis, primary biliary cholangitis, and respiratory syncytial virus.

Read More: What are the Different Types of Leveraged Buyouts?

Institutional Ownership by Quarter for Enanta Pharmaceuticals (NASDAQ:ENTA)

Receive News & Ratings for Enanta Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enanta Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.